E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Thoracic trauma |
Traumatisés thoraciques |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compare the length of the sessions of VNI under DEX and placebo in the thoracic trauma patient |
Comparer la durée des séances de VNI sous DEX et sous placebo chez le patient traumatisé thoracique |
|
E.2.2 | Secondary objectives of the trial |
1) To compare the safety of the patient during the session of VNI in DEX through hetero assessment scales (RASS) and self-assessment (EVA dyspnea, pain EVA, analgesic consumption during the sessions). 2) Compare the effectiveness of the VNI on arterial blood gases according to sedation 3) Evaluate the safety: a collection of the number of adverse events attributable to DEX at meetings. |
1) Comparer la tolérance du patient lors de la séance de VNI sous DEX via des échelles d'hétéro évaluation (RASS) et d'autoévaluation (EVA dyspnée, EVA douleur, consommation d'antalgique pendant les séances). 2) Comparer l'efficacité de la VNI sur la gazométrie artérielle en fonction de la sédation 3) Evaluer la sécurité : recueil du nombre d'effets indésirables imputables à la DEX au cours des séances. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patient hospitalized in intensive care or USC • Patient with a closed chest trauma not intubated (TTS score> 6) • Patient row to social security • Major Patient |
• Patient hospitalisé en réanimation ou USC • Patient présentant un traumatisme thoracique fermé non intubé (score TTS > 6) • Patient affilé à la sécurité sociale • Patient majeur |
|
E.4 | Principal exclusion criteria |
• EVA Rest> 3 • Agitation with RASS> 2 • Patient on DEX or treated with an alpha 2 agonist in the last 8 hours • Patients on home VNI (except for VS-PPC OSA) • analgesia by epidural catheter • Long-term treatment with neuroleptics • Contraindications to the VNI • Contraindications to the DEX |
• EVA repos>3 • Agitation avec RASS>2 • Patient sous DEX ou ayant reçu un alpha 2 agoniste dans les 8 dernières heures • Patient sous VNI à domicile (sauf VS-PPC pour SAOS) • Analgésie par Cathéter péridural • Traitement au long cours par neuroleptiques • Contre-indications à la VNI • Contre-indication à la DEX |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Duration of VNI sessions with and without DEX (minutes) |
Durée des séances de VNI avec et sans DEX (en mn) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |